Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females aged ≥ 40.~2. Patients with a clinical diagnosis of COPD according to GOLD guidelines 2014, with a post bronchodilator FEV1 ≥ 40% and \< 80% of the predicted value and FEV1/FVC \< 70% at Visit 1.~3. Functional residual capacity (FRC) measured by body plethysmography at Visit 1 ≥ 120% of predicted value.~4. Patients with modified Medical Research Council dyspnea scale (mMRC) ≥ 2 at Visit 1.~5. Current or former cigarette smokers with a smoking history of at least 10 pack-years at Visit 1~6. Patients willing to participate in the telecoaching program during the four last weeks and to enhance their physical activity~7. Patients who understand and are able to follow the study procedures, are cooperative and are willing to participate in the study as indicated by signing the informed consent.~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. Any respiratory tract infection (including upper respiratory tract) or COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period.~3. Patients who have been hospitalised for an acute COPD exacerbation within 3 months prior to Visit 1 or during the run-in period.~4. Clinically significant respiratory conditions other than COPD.~5. Use of long-term oxygen therapy (≥ 15 hours/day).~6. Oxygen saturation ≤ 85% as measured by pulse oximetry during exercise testing at Visit 1, Visit 2 or Visit 3 prior to randomisation.~7. Patients with a Body Mass Index (BMI) ≥ 40kg/m2.~8. Patient who may need to start a pulmonary rehabilitation program during the study and/or who started/finished it within 3 months prior to Visit 1 or during the run-in period.~9. Patients with clinically significant cardiovascular conditions.~10. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension.~11. Patient with known non-controlled history of infection with human immunodeficiency virus (HIV) and/or active hepatitis.~12. Patients with clinically relevant abnormalities in the results of the blood pressure, ECG, or physical examination at Visit 1.~13. Patients with any serious or uncontrolled physical or mental dysfunction that could place the patient at higher risk derived from his/her participation in the study or could confound the results~14. Patients with conditions other than COPD that may contribute to dyspnoea and exercise limitation or with contraindications to clinical exercise testing according to ATS recommendations for CPET~15. Patients with other relevant comorbidities that make the patient nor suitable to follow-up study procedures and/or could affect physical activity~16. Patients who cycled \< 2 minutes or \> 15 minutes during the constant work-rate exercise tests conducted at Visit 2 (Run-in Visit) or at Visit 3 even after adjustment of the work load.~17. Patients with history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines or inhaled medication or any component thereof (including report of paradoxical bronchospasm)~18. Patients for whom the use of anticholinergic drugs is contraindicated (acute urinary retention, symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma)~19. Patients unable to properly use a multidose dry powder inhaler or a pressurized metered-dose inhaler (pMDI).~20. Patients using any prohibited medication (including IMP within 30 days (or 6 half-lives, whichever is longer) before Visit 1) or who have not undergone the required washout period.~21. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer).~22. Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers, sleep apnea).~23. Patients unable to give their consent, or patients of consenting age but under guardianship, or vulnerable patients

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg (Type: EXPERIMENTAL): 8 weeks, double blind treatment period
- Placebo to Aclidinium/Formoterol (Type: PLACEBO_COMPARATOR): 8 weeks, double blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).